Novartis agreed to pay $310 million upfront, with the possibility for more later, for some research assets of Boston-based inflammation specialist IFM Therapeutics as the Swiss drugmaker expands the company’s immunology pipeline.
People with inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis may be up to 12 times more likely to have a heart attack, a U.S. study suggests.
Johnson & Johnson said the company’s blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.
Abivax – a biotechnology company harnessing the immune system to develop a functional cure for HIV, as well as treatments for inflammatory/autoimmune diseases and cancer – today announced top-line results from its Phase 2a clinical trial, ABX464-101.
Pfizer Inc. announced that the European Commission approved Xeljanz (tofacitinib citrate) 10 mg twice daily for at least eight weeks, followed by Xeljanz 5 mg BID or 10 mg BID, for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
The U.S. FDA approved Pfizer’s blockbuster drug Xeljanz to treat adults with moderate-to-severe active ulcerative colitis.
Janssen Pharmaceutical of Johnson & Johnson inked a global collaboration deal with Theravance Biopharma to develop a drug for inflammatory bowel diseases (IBD).
Celgene is scrapping a late-stage Crohn’s disease drug it acquired in a $710 million deal three years ago following an interim data analysis.
Irish drugmaker Shire Plc said it would buy the rights to an experimental bowel drug from Pfizer Inc to bolster its pipeline of gastrointestinal treatments.
Takeda Pharmaceuticals U.S.A. announced a multi-year research partnership with two world-leading academic centers with a proven long-term commitment to IBD research and care.